NZ755628A - Engineered phenylalanine ammonia lyase polypeptides - Google Patents
Engineered phenylalanine ammonia lyase polypeptidesInfo
- Publication number
- NZ755628A NZ755628A NZ755628A NZ75562818A NZ755628A NZ 755628 A NZ755628 A NZ 755628A NZ 755628 A NZ755628 A NZ 755628A NZ 75562818 A NZ75562818 A NZ 75562818A NZ 755628 A NZ755628 A NZ 755628A
- Authority
- NZ
- New Zealand
- Prior art keywords
- polypeptides
- engineered
- pal
- ammonia lyase
- phenylalanine ammonia
- Prior art date
Links
- 108700023158 Phenylalanine ammonia-lyases Proteins 0.000 title abstract 9
- 229920001184 polypeptide Polymers 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003197 catalytic effect Effects 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000017854 proteolysis Effects 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y403/00—Carbon-nitrogen lyases (4.3)
- C12Y403/01—Ammonia-lyases (4.3.1)
- C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Dermatology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458232P | 2017-02-13 | 2017-02-13 | |
| US201762565555P | 2017-09-29 | 2017-09-29 | |
| PCT/US2018/017773 WO2018148633A1 (en) | 2017-02-13 | 2018-02-12 | Engineered phenylalanine ammonia lyase polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ755628A true NZ755628A (en) | 2023-09-29 |
Family
ID=63106144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ755628A NZ755628A (en) | 2017-02-13 | 2018-02-12 | Engineered phenylalanine ammonia lyase polypeptides |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US10995329B2 (enExample) |
| EP (1) | EP3579867A4 (enExample) |
| JP (2) | JP2020505942A (enExample) |
| KR (1) | KR102573324B1 (enExample) |
| CN (1) | CN110573175A (enExample) |
| AU (1) | AU2018217495B2 (enExample) |
| BR (1) | BR112019016634A2 (enExample) |
| CA (1) | CA3051262A1 (enExample) |
| IL (1) | IL268226A (enExample) |
| MX (1) | MX2019009615A (enExample) |
| MY (1) | MY196740A (enExample) |
| NZ (1) | NZ755628A (enExample) |
| PH (1) | PH12019501705A1 (enExample) |
| SG (1) | SG11201906880VA (enExample) |
| WO (1) | WO2018148633A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3807409A4 (en) | 2018-06-12 | 2022-08-03 | Codexis, Inc. | Engineered tyrosine ammonia lyase |
| WO2021168060A1 (en) * | 2020-02-19 | 2021-08-26 | Trustees Of Tufts College | Methods for engineering amino acid ammonia lyase enzymes and enzymes thereby obtained |
| CN112355034B (zh) * | 2020-11-17 | 2021-08-06 | 同济大学 | 基于水热钙离子调配的有机固体废弃物无害化预处理方法 |
| CN115518691B (zh) * | 2022-10-14 | 2023-11-21 | 天津大学 | 一种具有类漆酶活性的人工酶及制备方法和应用 |
| AU2024289192A1 (en) | 2023-07-06 | 2026-01-08 | Perseo Pharma Ag | Method for immobilization of proteins |
| EP4739349A1 (en) | 2023-07-06 | 2026-05-13 | Perseo Pharma AG | Functionalized compositions comprising an engineered phenylalanine ammonia lyase (pal) |
| WO2026163257A1 (en) | 2025-01-29 | 2026-08-06 | Dr. Schär S.P.A. | Microorganism, production method and use for the treatment of phenylketonuria |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK75593D0 (enExample) * | 1993-06-25 | 1993-06-25 | Novo Nordisk As | |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6395547B1 (en) | 1994-02-17 | 2002-05-28 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US6309883B1 (en) | 1994-02-17 | 2001-10-30 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US6335160B1 (en) | 1995-02-17 | 2002-01-01 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6117679A (en) | 1994-02-17 | 2000-09-12 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US20060257890A1 (en) | 1996-05-20 | 2006-11-16 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5928905A (en) | 1995-04-18 | 1999-07-27 | Glaxo Group Limited | End-complementary polymerase reaction |
| US6165793A (en) | 1996-03-25 | 2000-12-26 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US6406855B1 (en) | 1994-02-17 | 2002-06-18 | Maxygen, Inc. | Methods and compositions for polypeptide engineering |
| US6995017B1 (en) | 1994-02-17 | 2006-02-07 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| CA2191718A1 (en) | 1994-06-03 | 1995-12-14 | Randy M. Berka | Phosphonyldipeptides useful in the treatment of cardiovascular diseases |
| ATE294871T1 (de) | 1994-06-30 | 2005-05-15 | Novozymes Biotech Inc | Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren |
| FI104465B (fi) | 1995-06-14 | 2000-02-15 | Valio Oy | Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö |
| US6096548A (en) | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
| US6506602B1 (en) | 1996-03-25 | 2003-01-14 | Maxygen, Inc. | Methods for generating polynucleotides having desired characteristics by iterative selection and recombination |
| WO1998031816A1 (en) | 1997-01-17 | 1998-07-23 | Regents Of The University Of Minnesota | Dna molecules and protein displaying improved triazine compound degrading ability |
| US7148054B2 (en) | 1997-01-17 | 2006-12-12 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| EP1717322B1 (en) | 1997-01-17 | 2012-07-18 | Codexis Mayflower Holdings, LLC | Evolution of whole cells and organisms by recursive sequence recombination |
| US6326204B1 (en) | 1997-01-17 | 2001-12-04 | Maxygen, Inc. | Evolution of whole cells and organisms by recursive sequence recombination |
| IL136574A0 (en) | 1997-12-08 | 2001-06-14 | California Inst Of Techn | A method for forming a polynucleotide of desired properties |
| CA2326835A1 (en) | 1998-04-02 | 1999-10-14 | Tellus Genetic Resources, Inc. | A method for obtaining a plant with a genetic lesion in a gene sequence |
| CN1314911A (zh) | 1998-05-01 | 2001-09-26 | 麦克西根股份有限公司 | 用dna改组优化害虫抗性基因 |
| JP2002517995A (ja) | 1998-06-17 | 2002-06-25 | マキシジェン， インコーポレイテッド | 所望の特性を有するポリヌクレオチドを生成するための方法 |
| US6365408B1 (en) | 1998-06-19 | 2002-04-02 | Maxygen, Inc. | Methods of evolving a polynucleotides by mutagenesis and recombination |
| EP1104459A1 (en) | 1998-08-12 | 2001-06-06 | Maxygen, Inc. | Dna shuffling of monooxygenase genes for production of industrial chemicals |
| AU6510799A (en) | 1998-10-07 | 2000-04-26 | Maxygen, Inc. | Dna shuffling to produce nucleic acids for mycotoxin detoxification |
| EP1129184A1 (en) | 1998-11-10 | 2001-09-05 | Maxygen, Inc. | Modified adp-glucose pyrophosphorylase for improvement and optimation of plant phenotypes |
| JP4221100B2 (ja) | 1999-01-13 | 2009-02-12 | エルピーダメモリ株式会社 | 半導体装置 |
| US6376246B1 (en) | 1999-02-05 | 2002-04-23 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6436675B1 (en) | 1999-09-28 | 2002-08-20 | Maxygen, Inc. | Use of codon-varied oligonucleotide synthesis for synthetic shuffling |
| US6368861B1 (en) | 1999-01-19 | 2002-04-09 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| US6917882B2 (en) | 1999-01-19 | 2005-07-12 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US6961664B2 (en) | 1999-01-19 | 2005-11-01 | Maxygen | Methods of populating data structures for use in evolutionary simulations |
| US7702464B1 (en) | 2001-08-21 | 2010-04-20 | Maxygen, Inc. | Method and apparatus for codon determining |
| US7024312B1 (en) | 1999-01-19 | 2006-04-04 | Maxygen, Inc. | Methods for making character strings, polynucleotides and polypeptides having desired characteristics |
| US8457903B1 (en) | 1999-01-19 | 2013-06-04 | Codexis Mayflower Holdings, Llc | Method and/or apparatus for determining codons |
| US20070065838A1 (en) | 1999-01-19 | 2007-03-22 | Maxygen, Inc. | Oligonucleotide mediated nucleic acid recombination |
| JP2002534965A (ja) | 1999-01-19 | 2002-10-22 | マキシジェン， インコーポレイテッド | 所望の特徴を有する文字ストリング、ポリヌクレオチドおよびポリペプチドを作製するための方法 |
| US7873477B1 (en) | 2001-08-21 | 2011-01-18 | Codexis Mayflower Holdings, Llc | Method and system using systematically varied data libraries |
| IL144657A0 (en) | 1999-02-11 | 2002-06-30 | Maxygen Inc | High throughput mass spectrometry |
| AU3391900A (en) | 1999-03-05 | 2000-09-21 | Maxygen, Inc. | Encryption of traits using split gene sequences |
| US6703240B1 (en) | 1999-04-13 | 2004-03-09 | Maxygar, Inc. | Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes |
| US7430477B2 (en) | 1999-10-12 | 2008-09-30 | Maxygen, Inc. | Methods of populating data structures for use in evolutionary simulations |
| US6519065B1 (en) | 1999-11-05 | 2003-02-11 | Jds Fitel Inc. | Chromatic dispersion compensation device |
| US6686515B1 (en) | 1999-11-23 | 2004-02-03 | Maxygen, Inc. | Homologous recombination in plants |
| SG121902A1 (en) | 2000-01-11 | 2006-05-26 | Maxygen Inc | Integrated systems for diversity generation and screening |
| AU4964101A (en) | 2000-03-30 | 2001-10-15 | Maxygen Inc | In silico cross-over site selection |
| AU2001249811B2 (en) | 2000-04-03 | 2006-06-08 | Maxygen, Inc. | Subtilisin variants |
| US7747391B2 (en) | 2002-03-01 | 2010-06-29 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| US20050084907A1 (en) | 2002-03-01 | 2005-04-21 | Maxygen, Inc. | Methods, systems, and software for identifying functional biomolecules |
| EP2315145B1 (en) | 2002-03-01 | 2015-11-25 | Codexis Mayflower Holdings, LLC | Methods, systems, and software for identifying functional biomolecules |
| WO2003078583A2 (en) | 2002-03-09 | 2003-09-25 | Maxygen, Inc. | Optimization of crossover points for directed evolution |
| US8003356B2 (en) | 2004-04-20 | 2011-08-23 | E. I. Du Pont De Nemours And Company | Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH |
| EP1869174B1 (en) | 2005-03-10 | 2015-02-18 | BASF Enzymes LLC | Lyase enzymes, nucleic acids encoding them and methods for making and using them |
| US7531341B1 (en) | 2006-06-12 | 2009-05-12 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7534595B2 (en) | 2006-06-12 | 2009-05-19 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof |
| US7537923B2 (en) | 2007-08-17 | 2009-05-26 | Biomarin Pharmaceutical Inc. | Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof |
| US8504498B2 (en) | 2008-02-12 | 2013-08-06 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| WO2009102901A1 (en) | 2008-02-12 | 2009-08-20 | Codexis, Inc. | Method of generating an optimized, diverse population of variants |
| US8383346B2 (en) | 2008-06-13 | 2013-02-26 | Codexis, Inc. | Combined automated parallel synthesis of polynucleotide variants |
| ES2705694T3 (es) | 2008-06-13 | 2019-03-26 | Codexis Inc | Método de síntesis de variantes de polinucleótidos |
| US20090312196A1 (en) | 2008-06-13 | 2009-12-17 | Codexis, Inc. | Method of synthesizing polynucleotide variants |
| WO2013003290A1 (en) | 2011-06-28 | 2013-01-03 | Codexis, Inc. | Protein variant generation by region shuffling |
| EP4062928A3 (en) | 2010-02-04 | 2022-11-30 | BioMarin Pharmaceutical Inc. | Prokaryotic phenylalanine ammonia-lyases and their use for treating phenylketonuria and hyperphenylalaninemia |
| CA2815341A1 (en) | 2010-11-05 | 2012-05-10 | Basf Plant Science Company Gmbh | Methods for increasing yield and fine chemical production in plants |
| WO2012122333A1 (en) | 2011-03-08 | 2012-09-13 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University | Microbial conversion of glucose to styrene and its derivatives |
| US20130005012A1 (en) | 2011-06-23 | 2013-01-03 | Phytogene, Inc. | Enzymatic system for monomer synthesis |
| US20150050658A1 (en) | 2012-03-15 | 2015-02-19 | Codexix, Inc. | Gene shuffling methods |
| RU2695146C2 (ru) | 2013-01-31 | 2019-07-22 | Кодексис, Инк. | Способы, системы и программное обеспечение для идентификации биомолекул со взаимодействующими компонентами |
| PL2986722T3 (pl) * | 2013-04-18 | 2019-10-31 | Codexis Inc | Skonstruowane polipeptydy amoniakoliazy fenyloalaniny |
| DK3049973T3 (en) | 2013-09-27 | 2018-10-22 | Codexis Inc | AUTOMATED SCREENING OF ENZYM VARIENTS |
| WO2015048573A1 (en) | 2013-09-27 | 2015-04-02 | Codexis, Inc. | Structure based predictive modeling |
| BR112016011195A2 (pt) | 2013-11-18 | 2017-09-19 | Rubius Therapeutics Inc | Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico |
-
2018
- 2018-02-12 AU AU2018217495A patent/AU2018217495B2/en not_active Ceased
- 2018-02-12 KR KR1020197025645A patent/KR102573324B1/ko active Active
- 2018-02-12 NZ NZ755628A patent/NZ755628A/en not_active IP Right Cessation
- 2018-02-12 JP JP2019543213A patent/JP2020505942A/ja active Pending
- 2018-02-12 CN CN201880025923.9A patent/CN110573175A/zh active Pending
- 2018-02-12 CA CA3051262A patent/CA3051262A1/en active Pending
- 2018-02-12 MX MX2019009615A patent/MX2019009615A/es unknown
- 2018-02-12 WO PCT/US2018/017773 patent/WO2018148633A1/en not_active Ceased
- 2018-02-12 MY MYPI2019004314A patent/MY196740A/en unknown
- 2018-02-12 EP EP18750620.9A patent/EP3579867A4/en not_active Withdrawn
- 2018-02-12 US US15/894,446 patent/US10995329B2/en not_active Expired - Fee Related
- 2018-02-12 SG SG11201906880VA patent/SG11201906880VA/en unknown
- 2018-02-12 BR BR112019016634A patent/BR112019016634A2/pt not_active Application Discontinuation
-
2019
- 2019-07-23 IL IL268226A patent/IL268226A/en unknown
- 2019-07-24 PH PH12019501705A patent/PH12019501705A1/en unknown
-
2021
- 2021-03-31 US US17/219,494 patent/US20210222145A1/en not_active Abandoned
-
2022
- 2022-05-17 JP JP2022080791A patent/JP2022103296A/ja active Pending
-
2023
- 2023-01-13 US US18/154,475 patent/US20230295599A1/en not_active Abandoned
- 2023-01-13 US US18/154,388 patent/US20230295598A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210222145A1 (en) | 2021-07-22 |
| EP3579867A4 (en) | 2021-03-10 |
| KR102573324B1 (ko) | 2023-08-30 |
| CN110573175A (zh) | 2019-12-13 |
| IL268226A (en) | 2019-09-26 |
| EP3579867A1 (en) | 2019-12-18 |
| KR20190117577A (ko) | 2019-10-16 |
| SG11201906880VA (en) | 2019-08-27 |
| CA3051262A1 (en) | 2018-08-16 |
| MX2019009615A (es) | 2019-10-14 |
| JP2022103296A (ja) | 2022-07-07 |
| AU2018217495B2 (en) | 2021-03-04 |
| US20180230448A1 (en) | 2018-08-16 |
| WO2018148633A1 (en) | 2018-08-16 |
| MY196740A (en) | 2023-05-03 |
| AU2018217495A1 (en) | 2019-08-08 |
| US10995329B2 (en) | 2021-05-04 |
| PH12019501705A1 (en) | 2020-07-06 |
| BR112019016634A2 (pt) | 2020-04-07 |
| US20230295598A1 (en) | 2023-09-21 |
| US20230295599A1 (en) | 2023-09-21 |
| JP2020505942A (ja) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019501705A1 (en) | Engineered phenylalanine ammonia lyase polypeptides | |
| PH12015502412A1 (en) | Engineered phenylalanine ammonia lyase polypeptides | |
| PH12017500785A1 (en) | INTERFERON a2B VARIANTS | |
| MX2019013289A (es) | Variantes de ligasa modificadas geneticamente. | |
| MX2016011745A (es) | Variantes de hppd y metodos de uso. | |
| PH12016500239A1 (en) | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof | |
| TN2012000372A1 (en) | Fibronectin based scaffold domain proteins that bind il-23 | |
| MX2024003743A (es) | Inmunoglobulinas de union a agrecano. | |
| EA201691811A1 (ru) | Варианты гфпд и способы их применения | |
| MX382321B (es) | Nuevo polipéptido con afinidad por pd-l1. | |
| MX356675B (es) | Polipeptidos interleuquina- 2 mutantes. | |
| MX2013007904A (es) | Anticuerpos anti-il-12/il-23 y usos de los mismos. | |
| EA200901430A1 (ru) | Варианты фермента аспарагиназы и их применение | |
| PH12018501114A1 (en) | Polypeptides inhibiting cd40l | |
| MX2014006399A (es) | Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca. | |
| HK1258349A1 (zh) | Hppd变体及使用方法 | |
| EA033145B1 (ru) | Применение полученных из pedf пептидов в стимуляции регенерации мышцы, регенерации сухожилия или артериогенеза | |
| MX2013003237A (es) | Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos. | |
| MX2013003236A (es) | Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos. | |
| NZ732978A (en) | Il-17a-binding polypeptides | |
| PH12016500320A1 (en) | Cyclosporin analogues for preventing or treating hepatitis c | |
| GB2517354A (en) | Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy | |
| SG10201805039UA (en) | Protease resistant peptides | |
| PH12018502656A1 (en) | Engineered beta-glucosidases and glycosylation methods | |
| PH12022551776A1 (en) | Engineered leucine decarboxylases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |